Achieving normoglycaemia with tirzepatide: Post hoc exploratory analysis of the SURPASS J‐mono and J‐combo studies
Authors' conclusion
Baseline HbA1c and body mass index, disease duration and the tirzepatide treatment group were shown to be predictive factors for achieving normoglycaemia. A lower baseline HbA1c was most strongly associated with normoglycaemia achievement.
Study context
- Population
- Japanese participants with T2D treated with tirzepatide in two phase 3 studies; mean age 56.7 years, 76% men
- Participants
- 912 participants2 pooled studies
- Comparison
- Participants achieving vs not achieving normoglycaemia on tirzepatide
- Normoglycaemian = 553
- Primary endpoint
- Predictive factors associated with achieving normoglycaemia (HbA1c <5.7%)
- Follow-up
- 52 weeks
Methodological detailspooled data, logistic regression
- Pooled data
- Logistic regression
Primary result
As reported in the abstract
Normoglycaemia
60.6%
553
- Lower baseline BMI associated with higher normoglycaemia rates
- P = 0.009
- Shorter disease duration associated with higher normoglycaemia rates
- P = 0.008
- Lower baseline HbA1c associated with higher normoglycaemia rates
- P < 0.001
- Tirzepatide 10 or 15 mg vs 5 mg associated with higher normoglycaemia rates
- P < 0.001
- Normoglycaemia in those with baseline HbA1c <8% and weight reduction ≥15%
- 94%
Further findings
| Outcome | Normoglycaemia | No normoglycaemia |
|---|---|---|
| Change from baseline in HbA1cMean, % | −2.87 (SD 0.95) | −2.47 (SD 1.1) |
| Change from baseline in body weightMean, kg | −10.30 (SD 5.8) | −3.75 (SD 4.3) |
Original publication
Achieving normoglycaemia with tirzepatide: Post hoc exploratory analysis of the SURPASS J‐mono and J‐combo studies. Diabetes Obes Metab. Published 27 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →